There's no two without three. AstraZeneca it also rejected the latest improved takeover bid made by the American company Pfizer, which had managed to raise up to about 117 billion dollars (over 85 billion euros).
The British pharmaceutical company claims that the new proposal of the US competitor, such as the previous two (100 and 106 billion respectively), you underestimate the company and its prospects.
The AstraZeneca Board of Directors also specified that it would have been willing to consider the offer if it had been 10% higher than the contained amount of Pfizer's proposal.
British public opinion exerted great pressure against the operation, leading Pfizer's top management to reassure publicly and before Crown MPs that they intend to keep research and jobs in Great Britain in any case.
From the marriage between the two companies, the largest pharmaceutical company in the world by sales would have been born, with headquarters in New York and tax headquarters in Great Britain, where Pfizer could have paid less taxes.
